Peer Review channel feed

Ex­clu­sive: GV’s first net­work de­vel­op­ment part­ner com­pletes ‘full cir­cle’; Just when En­zy­vant scores an ap­proval, Rachelle Jacques plans her ex­it

4 years ago

Till­man Gern­gross leads a pack of biotech CEOs out the door; With eyes on pipeline ex­pan­sion, Po­sei­da woos a gene ther­a­py ex­ec from No­var­tis

4 years ago

Am­gen, Ipsen vet moves up the lad­der with Co­herus' an­ti-PD-1 await­ing PDU­FA; It takes a vil­lage to re­place Frank Clyburn at Mer­ck­'s Hu­man Health busi­ness

4 years ago

With sotro­vimab in the bal­ance, Bio­gen vet re­unites with George Scan­gos at Vir; First woman to chair PhRMA has more in store at Take­da

4 years ago

Lyell CSO: New job is 'the miss­ing piece' of his ca­reer; Or­p­hazyme and Cor­texyme and Sio, oh my: Your guide to the lat­est CEO changes

4 years ago

Blue­print Med­i­cines gets more ducks in a row be­fore CEO tran­si­tion; Paul Stof­fels has his work cut out for him at Gilead’s crum­bling part­ner

4 years ago

As Hal Bar­ron steals the show, there’s no off po­si­tion on the John Maraganore switch; Dan­ny Bar-Zo­har makes an­oth­er leap for­ward at Mer­ck KGaA

4 years ago

Er­ic Os­tertag reach­ing the end of the line as Po­sei­da chief, will be­come ex­ec­u­tive chair­man; Alec­tor ex­ec named CEO of Pfiz­er-backed LNP biotech

4 years ago

How fam­i­ly and sci­ence moved Ex­elix­is' new CMO to work on on­col­o­gy block­busters; While John Maraganore racks up the prizes, his old crew at Al­ny­lam se­lects pres­i­dent

4 years ago

Joan Shen ends the year by say­ing good­bye to I-Mab; CRISPR Ther­a­peu­tics puts coal in R&D chief's stock­ing

4 years ago

Sara Kenkare-Mi­tra leaves Genen­tech for a chance to lead neu­ro R&D; Glax­o­SmithK­line alum jumps to Vi­for Phar­ma with the lid lift­ed on sale to CSL

4 years ago

Flag­ship on cen­ter stage: Ax­cel­la’s new CMO likens the biotech to ‘pro­fes­sion­al sports team’; Life af­ter the FDA takes shape for Stephen Hahn as a chief ex­ec­u­tive

4 years ago

Joseph Ar­ron march­es to the beat of his own drum at 23andMe; Ex-Voy­ager CFO joins Sek Kathire­san at Verve Ther­a­peu­tics

4 years ago

Tak­ing a leave of ab­sence, Am­pio Phar­ma­ceu­ti­cals CEO pass­es ba­ton to a new board mem­ber; Ax­el Hoos' can­cer biotech lands a CFO

4 years ago

Take­da on­col­o­gy vet drills down the 'ba­sic­s' at cell ther­a­py start­up; Sarep­ta pro­motes new R&D chief

4 years ago

Cy­toIm­mune CEO breaks down her 3 'pil­lars' of suc­cess; For­mer No­var­tis, Gilead ex­ec Alessan­dro Ri­va to lead an ul­tra low-pro­file cell ther­a­py out­fit

4 years ago

Pierre Beau­rang hits the ground run­ning at his 3rd start­up; Mike Grey poach­es Astel­las deal­mak­er to head pro­tein degra­da­tion play­er

4 years ago

Al­ny­lam’s John Maraganore isn’t the on­ly CEO to leave his post; CRISPR’s chief com­mer­cial of­fi­cer takes the helm at a pro­tein degra­da­tion play­er

4 years ago

Brid­get Martell on tak­ing Yale spin­out 'to adult­hood'; Cul­li­nan On­col­o­gy CEO an­nounces res­ig­na­tion as Bris­tol My­ers hema­tol­ogy ex­ec is wel­comed aboard

4 years ago

Lu­ba Green­wood takes the helm at Ko­jin Ther­a­peu­tics, steer­ing an all-fe­male C-suite; Alex­ion R&D chief packs up for change of scenery at VC firm

4 years ago

Flag­ship turns to No­var­tis HR gu­ru in lat­est ad­di­tion; David Grainger sad­dles up to new po­si­tion at Centes­sa while Pfiz­er's Rod MacKen­zie pre­pares to ride in­to the sun­set

4 years ago

Sporos Bioven­tures taps first CEO dur­ing pe­ri­od of 'ex­plo­sive growth'; In the wake of murky Hunter syn­drome da­ta, De­nali bulks up C-suite

4 years ago

With Mav­er­ick now in Takeda's hands, James Sci­bet­ta turns the page; Roivant CMO leaves in fa­vor of small IL-2 biotech

4 years ago

A Pfiz­er part­ner wel­comes ex-ADC Ther­a­peu­tics CMO Jay Fein­gold to the team; Amid tough sled­ding, Im­muno­vant choos­es Eli Lil­ly alum as CFO

4 years ago
First page Previous page 567891011 Next page Last page
A service from the Financial Times